SGRY Stock Analysis: Surgery | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 2.004m USD | 12M Return: -33.1% | US86881A1007 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 21.8M
EPS Trend: -52.2%
Qual. Beats: 1
Rev. Trend: 98.6%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Surgery Partners, Inc. (SGRY) operates a U.S. network of surgical facilities and ancillary healthcare services, primarily through ambulatory surgery centers (ASCs) and surgical hospitals that perform non-emergency procedures. Its clinical mix spans orthopedics and pain management, ophthalmology, gastroenterology, and general surgery, and it also runs emergency departments, physician practices, diagnostic testing, urgent care, and anesthesia services.
The company was founded in 2004, is headquartered in Brentwood, Tennessee, and has traded on NASDAQ since its October 2015 IPO. Surgery Partners sits within the GICS Health Care Facilities sub-industry, a segment shaped by the ongoing migration of lower-acuity procedures from inpatient hospital settings to lower-cost outpatient facilities.
- Same-store procedure volumes accelerate across ASC network
- Reimbursement pressure and labor costs squeeze margins
- ASC acquisitions and consolidation drive facility network expansion
| Net Income: -76.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.41 > 1.0 |
| NWC/Revenue: 14.98% < 20% (prev 15.92%; Δ -0.94% < -1%) |
| CFO/TA 0.03 > 3% & CFO 280.0m > Net Income -76.1m |
| Net Debt (4.16b) to EBITDA (958.2m): 4.34 < 3 |
| Current Ratio: 1.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (128.4m) vs 12m ago 1.39% < -2% |
| Gross Margin: 21.68% > 18% (prev 23.71%; Δ -2.03% > 0.5%) |
| Asset Turnover: 41.82% > 50% (prev 39.91%; Δ 1.90% > 0%) |
| Interest Coverage Ratio: 1.17 > 6 (EBIT TTM 780.0m / Interest Expense TTM 666.1m) |
| A: 0.06 (Total Current Assets 1.08b - Total Current Liabilities 581.7m) / Total Assets 8.04b |
| B: -0.11 (Retained Earnings -851.1m / Total Assets 8.04b) |
| C: 0.10 (EBIT TTM 780.0m / Avg Total Assets 8.00b) |
| D: 0.37 (Book Value of Equity 1.69b / Total Liabilities 4.56b) |
| Altman-Z'' = 1.11 = BB |
| DSRI: 1.00 (Receivables 603.4m/570.6m, Revenue 3.34b/3.17b) |
| GMI: 1.09 (GM 23.71% / 21.68%) |
| AQI: 1.01 (AQ_t 0.69 / AQ_t-1 0.69) |
| SGI: 1.05 (Revenue 3.34b / 3.17b) |
| TATA: -0.04 (NI -76.1m - CFO 280.0m) / TA 8.04b) |
| Beneish M = -2.90 (Cap -4..+1) = A |
As of August 08, 2026, the stock is trading at USD 15.53 with a total of 1,864,674 shares traded. Over the past week, the price has changed by +0.84%, over one month by -9.55%, over three months by +8.53% and over the past year by -33.12%.
Current recommended Stop Loss: 14.40 (which is 7.3% or 1.4 ATR below the current price).
Surgery has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy SGRY.
- StrongBuy: 8
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 18.6 | 20% |
P/E Forward = 22.3214
P/S = 0.5993
P/B = 1.192
P/EG = 1.66
Revenue TTM = 3.34b USD
EBIT TTM = 780.0m USD
EBITDA TTM = 958.2m USD
Long Term Debt = 3.61b USD (from longTermDebt, last quarter)
Short Term Debt = 142.6m USD (from shortTermDebt, last quarter)
Debt = 4.34b USD (from shortLongTermDebtTotal, last quarter) + Leases 314.1m
Net Debt = 4.16b USD (calculated: Debt 4.34b - CCE 182.3m)
Enterprise Value = 6.16b USD (2.00b + Debt 4.34b - CCE 182.3m)
Interest Coverage Ratio = 1.17 (Ebit TTM 780.0m / Interest Expense TTM 666.1m)
EV/FCF = 29.63x (Enterprise Value 6.16b / FCF TTM 208.0m)
FCF Yield = 3.37% (FCF TTM 208.0m / Enterprise Value 6.16b)
FCF Margin = 6.22% (FCF TTM 208.0m / Revenue TTM 3.34b)
Net Margin = -2.28% (Net Income TTM -76.1m / Revenue TTM 3.34b)
Gross Margin = 21.68% ((Revenue TTM 3.34b - Cost of Revenue TTM 2.62b) / Revenue TTM)
Gross Margin QoQ = 15.01% (prev 23.98%)
Tobins Q-Ratio = 0.77 (Enterprise Value 6.16b / Total Assets 8.04b)
Interest Expense / Debt = 15.34% (Interest Expense 666.1m / Debt 4.34b)
Taxrate = 14.75% (16.8m / 113.9m)
NOPAT = 665.0m (EBIT 780.0m * (1 - 14.75%))
Current Ratio = 1.86 (Total Current Assets 1.08b / Total Current Liabilities 581.7m)
Debt / Equity = 2.57 (Debt 4.34b / totalStockholderEquity, last quarter 1.69b)
Debt / EBITDA = 4.34 (Net Debt 4.16b / EBITDA 958.2m)
Debt / FCF = 20.00 (Net Debt 4.16b / FCF TTM 208.0m)
Total Stockholder Equity = 1.72b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.95% (Net Income -76.1m / Total Assets 8.04b)
RoE = -4.43% (Net Income TTM -76.1m / Total Stockholder Equity 1.72b)
RoCE = 14.63% (EBIT 780.0m / Capital Employed (Equity 1.72b + L.T.Debt 3.61b))
RoIC = 8.94% (NOPAT 665.0m / Invested Capital 7.44b)
WACC = 11.43% (E(2.00b)/V(6.35b) * Re(7.87%) + D(4.34b)/V(6.35b) * Rd(15.34%) * (1-Tc(0.15)))
Discount Rate = 7.87% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.22 | Cagr: 0.91%
[DCF] Terminal Value 68.67% ; FCFF base≈194.1m ; Y1≈222.5m ; Y5≈327.5m
[DCF] Fair Price = N/A (negative equity: EV 3.18b - Net Debt 4.16b = -975.0m; debt exceeds intrinsic value)
EPS Correlation: -52.24 | EPS CAGR: -16.52% | SUE: 1.43 | # QB: 1
Revenue Correlation: 98.62 | Revenue CAGR: 9.69% | SUE: 0.95 | # QB: 2
EPS current Quarter (2026-06-30): EPS=0.07 | Chg30d=+6.70% | Revisions=+0% | Analysts=10
EPS next Quarter (2026-09-30): EPS=0.13 | Chg30d=+2.31% | Revisions=+0% | Analysts=10
EPS current Year (2026-12-31): EPS=0.46 | Chg30d=+3.94% | Revisions=+25% | GrowthEPS=-1.2% | GrowthRev=+3.0%
EPS next Year (2027-12-31): EPS=0.67 | Chg30d=+2.20% | Revisions=+40% | GrowthEPS=+43.9% | GrowthRev=+5.3%
[Analyst] Revisions Ratio: +50% (up=3, down=0)